Glycoside derivatives and uses thereof

US9895389B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9895389-B2
Application numberUS-201615134016-A
CountryUS
Kind codeB2
Filing dateApr 20, 2016
Priority dateOct 20, 2009
Publication dateFeb 20, 2018
Grant dateFeb 20, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

First claim

Opening claim text (preview).

We claim: 1. A method of treating obesity, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 2. A method of treating obesity, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 3. A method of treating obesity, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 4. A method of treating obesity, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof.

Assignees

Inventors

Classifications

  • Antihypertensives · CPC title

  • for hyperglycaemia, e.g. antidiabetics · CPC title

  • Antihyperlipidemics · CPC title

  • Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

  • for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9895389B2 cover?
This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
Who is the assignee on this patent?
Novartis Ag
What technology area does this patent fall under?
Primary CPC classification A61K31/7052. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).